Litcius/Paper detail

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, Susana Puig, Paolo A. Ascierto, James Larkin, Paul Lorigan, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Thierry Lesimple, Michele Maio, Gerald P. Linette, Laurent Mortier, Inge Marie Svane, Jacob Schachter, Michael P. Brown, Peter Hersey, Catherine Barrow, Ragini R. Kudchadkar, Caroline Dutriaux, Xinni Song, Pietro Quaglino, Paola Queirolo, Friedegund Meier, Daniil Stroyakovskiy, B. Guillot, Pablo L. Ortiz‐Romero, Lars Bastholt, Claus Garbe, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Carmen Loquai, Frank Meiß, Vanna Chiarion‐Sileni, Gil Bar‐Sela, Bernard M. Fitzharris, Philippe Saïag, Jean‐Philippe Arnault, Jan‐Christoph Simon, Rosalie Stephens, Jean‐François Baurain, Célèste Lebbé, P. Combemale, Reinhard Dummer, Axel Hauschild, Phillip Parente, Naoya Yamazaki, Mohammed Milhem, M.‐T. Leccia, L. Geoffrois, Lutz Kretschmer, Elaine Dunwoodie, John Walker, Michal Lotem, Daniel Hendler, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Marcin Dzienis, Geke A.P. Hospers, Marco Siano, Jessica C. Hassel, Philippa Corrie, Maria-Jose Passos, Max Levin, Christoph Höeller, L. Machet, Sigrun Hallmeyer, Ashita Waterston, V. Descamps, Felix Kiecker, Maureen J.B. Aarts, Henrik Schmidt

2021The Lancet Oncology72 citationsDOIOpen Access PDF

Topics & Concepts

PembrolizumabMedicineClinical endpointHazard ratioPlaceboInternal medicineQuality of life (healthcare)PopulationClinical trialAdverse effectOncologyMelanomaRandomized controlled trialSurgeryCancerConfidence intervalPathologyImmunotherapyAlternative medicineNursingCancer researchEnvironmental healthCancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementMelanoma and MAPK Pathways
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial | Litcius